KANTO DENKA KOGYO CO.,LTD. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Revenue and profit both increased substantially, resulting in higher revenue and higher earnings as improvements in pricing and product mix dramatically enhanced profitability. Revenue was ¥19.77B (+30.6% year on year), Operating Income was ¥3.98B (+410.7%), Ordinary Income was ¥4.57B (+515.5%), and Net Income was ¥3.25B (+488.9%). The primary factor was margin expansion driven by improved demand and pricing in the Precision Chemicals Business, with the Operating Income margin surging from approximately 3.8% in the previous year to 20.1%.

Factors Affecting Financial Results

【Revenue】Revenue was ¥19.77B, up +30.6% year on year. The Precision Chemicals Business led growth, generating ¥16.52B (+38.3%) and accounting for 80.8% of total revenue, while the Equipment Business declined to ¥0.82B (-21.7%). The Basic Chemicals, Iron-Based Products, and Trading businesses posted only modest revenue increases.

【Profit and Loss】Operating Income was ¥3.98B (+410.7%), the gross margin expanded to 34.4%, and the SG&A ratio declined to 14.3%, resulting in operating leverage. Ordinary Income was ¥4.57B (+515.5%), supported by non-operating income including foreign exchange gains of ¥0.44B and dividend income of ¥0.24B. Extraordinary losses were a minor ¥0.01B. Net Income was ¥3.25B (+488.9%). The results reflect both revenue and earnings growth, with improved profitability attributable to both changes in product mix and cost efficiencies.

Segment Analysis

The Precision Chemicals Business generated revenue of ¥16.52B (+38.3%), Operating Income of ¥3.75B (+550.3%), and a profit margin of 22.7%, producing nearly all of the Company-wide profit. The Iron-Based Products Business remained solid, with revenue of ¥0.55B (+3.2%) and a profit margin of 18.9%. Basic Chemicals generated revenue of ¥2.08B (+6.1%), but its profit margin was low at 3.4%. The Trading Business recorded Operating Income of ¥0.04B, down -20.4% year on year. The Equipment Business generated revenue of ¥0.82B (-21.7%) and posted an Operating Loss of ¥0.01B, falling into the red, highlighting the pronounced polarization in profitability among segments. The high dependence on Precision Chemicals, which accounts for 80.8% of revenue, warrants attention as a future source of volatility.

Key Financial Indicators

【Profitability】The Operating Income margin was 20.1% and the Net Income margin was 16.4%, representing substantial improvements from the previous year’s Operating Income margin of 5.1% and Net Income margin of 3.6%. The gross margin also expanded to 34.4%, supported by pricing and product-mix factors as well as cost controls.【Cash Flow Quality】Inventories increased to ¥9.20B (¥6.59B in the previous year), while accounts receivable and notes receivable increased to ¥19.67B (¥17.64B in the previous year), indicating that working capital expansion is outpacing earnings growth.【Investment Efficiency】ROE was 4.2%, with the low total asset turnover ratio structurally constraining capital efficiency.【Financial Soundness】The Equity Ratio remained high at 55.4% (55.1% in the previous year). The Company held cash and deposits of ¥18.65B against long-term borrowings of ¥25.44B, indicating a sound financial base.

Cash Flow Analysis

As the cash flow statement is not disclosed in this report, funding trends are analyzed based on changes in the balance sheet. Inventories increased +39.6% year on year, while short-term borrowings increased +182.2%; both rose substantially, indicating that heightened working capital requirements associated with business expansion are being reflected in financing activities. Meanwhile, cash and deposits stood at ¥18.65B, slightly below ¥20.22B in the previous year, suggesting that part of the inventory buildup and funding requirements may have been absorbed through a reduction in cash on hand and short-term borrowings. The Equity Ratio remained at 55.4%, and long-term borrowings declined from the previous year, indicating that the overall financing structure continues to reflect a conservative stance.

Quality of Earnings

Recurring earnings are centered on Operating Income, while extraordinary losses of ¥0.01B were minor relative to Net Income, indicating limited effects from temporary factors. Of non-operating income of ¥0.75B, foreign exchange gains accounted for ¥0.44B, equivalent to approximately 11% of Operating Income and approximately 9.6% of Ordinary Income, making this a highly volatile item. Dividend income of ¥0.24B can be regarded as a stable source of earnings. The difference between Ordinary Income and Net Income is primarily attributable to income taxes of ¥1.32B. The effective tax rate was approximately 28.9% of pre-tax income of ¥4.56B, a standard level. Increases in inventories and accounts receivable suggest a possible timing mismatch in cash conversion relative to earnings growth. From an accrual perspective, monitoring future inventory sell-through and collection trends would be useful.

Earnings Forecast and Guidance

Progress against the Full-Year forecast was 20.8% for revenue (¥19.77B against the forecast of ¥95.00B), 35.2% for Operating Income (¥3.98B against the forecast of ¥11.30B), and 42.8% for Net Income (¥3.25B against the forecast of ¥0.76B). While revenue progress was slightly below a simple one-quarter benchmark of 25%, profit progress was substantially ahead, indicating that margin improvement in Q1 has pulled forward earnings progress. The earnings forecast was revised during the quarter, making the accuracy of the Full-Year outlook a key focus going forward. The dividend forecast was unchanged at 36 yen.

Shareholder Returns

The Full-Year dividend forecast is 36 yen per share, an increase from the previous year’s dividend of 9 yen (actual result before the aggregation of the interim and year-end dividends). Based on forecast EPS of 132.51 yen, the Payout Ratio is approximately 27.2%, remaining conservative relative to the earnings level. No disclosure regarding share buybacks was made, and the shareholder return policy is centered on dividends. As earnings progress is ahead of schedule in the current fiscal year, the Full-Year Payout Ratio may change after the financial results are finalized.

Risk Factors

1. Business concentration risk: The Precision Chemicals Business accounts for 80.8% of revenue and nearly all Operating Income, so fluctuations in demand and pricing in this business could have a significant impact on overall results.

2. Working capital expansion risk: Inventories increased +39.6% year on year, while accounts receivable and notes receivable increased +11.5%, creating the possibility that cash collection and inventory sell-through may lag earnings growth.

3. Foreign exchange sensitivity: Foreign exchange gains of ¥0.44B included in non-operating income account for approximately 9.6% of Ordinary Income. If foreign exchange trends reverse, Ordinary Income could be materially affected.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability significantly exceeds the industry median and is positioned in the upper range.

Growth and Capital Efficiency

The revenue growth rate is also outstanding within the industry, placing the Company in the upper tier in terms of growth.

Source: Company aggregation

Key Points from the Financial Results

1. Improvements in pricing and product mix and greater cost efficiency in the Precision Chemicals Business expanded the Operating Income margin to 20.1%, substantially above the industry median. Whether this improvement is structural or attributable to temporary market conditions needs to be confirmed through trends over multiple future quarters.

2. Profit progress against the Full-Year forecast is ahead of schedule, at 35.2% for Operating Income and 42.8% for Net Income. It is useful to assess this performance while considering the contribution of foreign exchange gains to Ordinary Income.

3. The pace of increase in inventories and accounts receivable is exceeding revenue growth. Trends in working capital will be a key factor affecting future cash generation, making developments from the next quarter onward an area of focus.

Theoretical Share Price (Reference Value)

Sensitivity: 1,335 yen–1,414 yen at ±1% for the cost of equity, and 1,372 yen–1,375 yen at ±0.1 for ω.

Notes:

• As Net Income progress against the Full-Year forecast (43%) exceeds the standard benchmark (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts. For businesses with strong seasonality, the adjustment may be excessive).
• Net assets at the end of the quarter are used (there is a timing mismatch with the Full-Year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this does not constitute a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information aggregated by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Kanto Denka delivered a very strong FY2027 Q1 earnings recovery, led decisively by its Precision Chemicals business. Revenue rose 30.6% year on year to ¥19.77bn. Operating income surged 410.7% to ¥3.98bn, substantially outpacing top-line growth. Profit attributable to owners of the parent increased 509.3% to ¥3.24bn. The operating margin expanded to 20.1% from 5.1% a year earlier, a 1,500bp improvement. Gross margin rose to 34.4% from 21.5%, or approximately 1,290bp, indicating that the earnings acceleration was principally gross-profit driven rather than solely attributable to fixed-cost control. SG&A expenses increased 13.5% to ¥2.82bn, materially below revenue growth, providing additional operating leverage. Ordinary income grew 515.5% to ¥4.57bn and exceeded operating income by ¥0.59bn. This non-operating uplift was mainly supported by ¥437m of foreign-exchange gains and ¥242m of dividend income. Net margin reached 16.4%, compared with 3.5% in the prior-year quarter. The reported annualized ROE was 16.6%, above the 15% level generally regarded as strong. The balance sheet remains liquid, with a 209.6% current ratio and a 183.2% quick ratio. However, short-term borrowings rose 182.2% year on year to ¥7.25bn, while inventories increased 39.6% to ¥9.20bn. Working-capital intensity remains the principal operating issue, as quality alerts identify receivable days of 91 days, extended production-inventory days of 196 days, and a 234-day cash conversion cycle. Management's full-year forecast implies revenue growth of 45.3% and operating-income growth of 106.2%, with Q1 operating-profit progress already at 35.2%. The quarterly result therefore provides an encouraging start to the revised full-year outlook, although sustaining the very high Q1 margin and converting inventory and receivables into cash are central monitoring points.

Profitability Analysis

The reported annualized ROE of 16.6% decomposes into a 16.4% net profit margin, 0.562x asset turnover, and 1.81x financial leverage. The key driver of return improvement is profitability: the 16.4% net margin compares with roughly 3.5% in FY2026 Q1, while the quarter generated an operating-margin expansion of 1,500bp to 20.1%. Asset turnover remains moderate for a capital-intensive chemical producer, reflecting ¥51.37bn of PPE, equivalent to 36.5% of total assets. Financial leverage is moderate rather than aggressive, with a 0.81x debt-to-equity ratio and debt/capital of 29.5%; thus, the ROE result is not primarily debt-engineered. The gross margin improved by approximately 1,290bp to 34.4%, demonstrating a sharp improvement in sales mix, pricing, production economics, or a combination of these factors. SG&A rose only 13.5%, versus 30.6% revenue growth, and the SG&A-to-sales ratio declined to 14.3% from 16.4%, adding around 210bp of operating leverage. Precision Chemicals was the core business, contributing ¥3.75bn of segment profit, or about 95% of aggregate segment profit before eliminations. Its segment profit increased from ¥577m to ¥3.75bn, while revenue grew 38.3% to ¥16.52bn; its segment margin consequently rose to 22.7% from 4.8%. Basic Chemicals generated ¥71m of profit, up 82.1%, on revenue growth of 6.1% to ¥2.08bn. Iron-based operations earned ¥104m, up 55.2%, on 3.2% revenue growth to ¥550m. Trading operations generated ¥39m of profit, down 20.4%, despite a 19.4% increase in external sales to ¥209m. Equipment operations recorded a ¥15m segment loss, compared with a ¥46m profit a year earlier, as external revenue fell 21.7% to ¥412m. Ordinary income benefited from ¥437m of FX gains, equal to 11.0% of operating income, so the earnings profile includes a meaningful currency-related uplift beyond the underlying operating recovery. The ¥12m fixed-asset disposal loss was immaterial at 0.4% of net income, leaving the quarter's net-profit result predominantly recurring in character.

Growth Assessment

Growth was highly concentrated in Precision Chemicals, where ¥4.58bn of incremental revenue accounted for nearly all of the consolidated ¥4.63bn year-on-year revenue increase. The segment's profit expansion of ¥3.18bn exceeded consolidated operating-income growth because other segments made a comparatively limited contribution and Equipment moved into loss. This concentration makes the sustainability of Precision Chemicals demand, product mix, utilization, and pricing the primary determinant of group earnings momentum. The 30.6% group revenue increase and 410.7% operating-income increase demonstrate strong positive operating leverage. Gross-profit growth of 108.3% also suggests that the improvement cannot be explained by revenue volume alone. The full-year forecast calls for ¥95.0bn of revenue, ¥11.3bn of operating income, ¥11.3bn of ordinary income, and ¥7.6bn of profit attributable to owners. Q1 revenue represents 20.8% of the full-year target, 4.2 percentage points below the standard 25% first-quarter pace and consistent with substantial revenue being expected later in the year. Q1 operating income represents 35.2% of forecast, 10.2 percentage points above a standard first-quarter pace. Q1 profit attributable to owners represents 42.6% of forecast, 17.6 percentage points above the standard pace. The profit-progress outperformance reflects both strong core profitability and FX gains, while the revenue progress profile indicates that maintaining utilization and demand through subsequent quarters remains important. The revised forecast embeds a lower full-year operating margin of 11.9% than Q1's 20.1%, indicating management does not assume the Q1 profitability level persists throughout the year. This leaves scope for forecast resilience if Q1 conditions partly normalize, but it also means quarterly margin trends should be assessed against the implied normalization.

Financial Health

Liquidity is sound: current assets of ¥72.95bn cover current liabilities of ¥34.81bn by 2.10x, and the 1.83x quick ratio shows that liquidity does not depend primarily on inventory realization. Working capital totals ¥38.15bn. Cash and deposits of ¥18.65bn cover short-term loans of ¥7.25bn by 2.57x. Interest-bearing debt totals ¥32.69bn, comprising ¥7.25bn of short-term loans and ¥25.44bn of long-term loans. The short-term debt ratio is 22.2%, limiting refinancing concentration, although ¥9.13bn of current portions of long-term loans are included within current liabilities and should remain an important maturity-management consideration. Debt-to-equity of 0.81x and debt/capital of 29.5% are within conservative credit benchmarks and do not indicate excessive balance-sheet leverage. Interest coverage is strong at 29.47x, supported by quarterly EBIT of ¥3.98bn relative to ¥135m of interest expense. Total equity increased ¥3.69bn year on year to ¥77.94bn, with retained earnings rising ¥2.60bn to ¥59.89bn. Short-term loans increased ¥4.68bn, or 182.2%, to ¥7.25bn; this is the most notable financing change and increases reliance on short-tenor funding even though cash coverage remains ample. Inventories rose ¥2.61bn, or 39.6%, to ¥9.20bn, tying up additional capital during a period of expanding sales. PPE remains substantial at ¥51.37bn, including ¥21.71bn of machinery and ¥5.57bn of construction in progress, consistent with the company's capital-intensive chemical manufacturing base. Investment securities of ¥14.46bn represent 10.3% of assets, and the associated valuation reserve contributes to equity sensitivity to market-price movements. Intangible assets are only ¥718m, or 0.5% of assets, indicating limited balance-sheet exposure to acquired intangibles.

Notable B/S Changes

Short-term loans: +¥4.68bn (+182.2%) to ¥7.25bn - materially higher short-term funding use; cash coverage remains strong at 2.57x, but refinancing and working-capital funding should be monitored. Inventories: +¥2.61bn (+39.6%) to ¥9.20bn - growth exceeded the 30.6% increase in revenue, reinforcing the elevated inventory-days and cash-conversion-cycle risk. Accounts receivable: +¥2.03bn (+11.5%) to ¥19.67bn - the absolute balance remains material and aligns with the 91-day receivable-period alert. Investment securities: +¥2.28bn (+18.7%) to ¥14.46bn - securities equal 10.3% of total assets and contribute to equity sensitivity through valuation differences. Cash and deposits: -¥1.57bn (-7.8%) to ¥18.65bn - liquidity remains ample, but the decline occurred alongside higher short-term borrowings and inventory investment.

Cash Flow Quality

The earnings-to-cash conversion assessment should focus on working-capital discipline. Quality alerts identify annualized receivable days of 91 days, above the 60-day warning threshold, indicating that collections are slow relative to sales. The accounts-receivable balance increased 11.5% year on year to ¥19.67bn, broadly consistent with higher revenue but still significant in absolute terms. The production-inventory measure produces annualized inventory days of 196 days, well above the 90-day warning threshold, pointing to a long manufacturing and stockholding cycle. A separate balance-sheet inventory measure produces 65 days, which is also above the 60-day manufacturing benchmark; both measures therefore indicate elevated inventory intensity. The inventory build is particularly relevant because inventories increased 39.6%, faster than 30.6% revenue growth. The resulting annualized cash conversion cycle of 234 days is substantially above the 120-day warning level. This long cycle elevates the risk that accounting earnings are not converted into operating cash as promptly as the income statement implies. It also increases exposure to demand volatility, product-mix changes, inventory valuation pressure, and additional funding needs if collections lengthen further. Accounts payable were broadly stable at ¥7.42bn, while electronically recorded obligations increased to ¥3.82bn from ¥1.62bn, providing some supplier-credit support but not fully offsetting the larger receivable and inventory commitment. The combination of strong margins and elevated working-capital days makes receivable collection, inventory turnover, and the cash conversion cycle the key indicators of earnings quality in subsequent quarters.

Dividend Sustainability

The full-year dividend forecast is ¥36.00 per share, unchanged despite the forecast revision. Based on forecast EPS of ¥132.51, the implied dividend payout ratio is 27.2%. This is well below the 60% sustainability benchmark and leaves a substantial earnings retention buffer. The forecast dividend commitment equates to approximately ¥2.07bn using 57.55 million issued shares, compared with forecast profit attributable to owners of ¥7.60bn. Retained earnings of ¥59.89bn further support the company's capacity to maintain its planned dividend. The balance sheet also provides support through a 209.6% current ratio, ¥18.65bn cash balance, and moderate 0.81x debt-to-equity. Dividend resilience nevertheless depends on working-capital conversion because elevated receivable and inventory days can absorb liquidity despite strong reported profits. The low forecast payout provides flexibility to absorb operational volatility without placing material pressure on the capital structure.

Risk Assessment

Business risks include Precision Chemicals concentration: the segment contributed about 95% of aggregate segment profit before eliminations, making group earnings highly sensitive to its demand, pricing, product mix, utilization, and customer conditions., Chemical manufacturing cycle risk: elevated production-inventory days of 196 days and a 39.6% inventory increase increase exposure to demand reversals, inventory valuation pressure, and potential obsolescence., Foreign-exchange risk: ¥437m of FX gains represented 11.0% of operating income, meaning currency movements provided a meaningful boost to ordinary income and may reverse., Segment execution risk: Equipment shifted from a ¥46m profit to a ¥15m loss as revenue declined 21.7%, while Trading profit fell 20.4%., Capital-intensive asset base: PPE represents 36.5% of total assets, requiring sustained operating utilization and disciplined maintenance and expansion investment..

Financial risks include Short-term loans rose ¥4.68bn year on year to ¥7.25bn, increasing short-tenor funding exposure despite adequate cash coverage., Receivable days of 91 days, production-inventory days of 196 days, and a 234-day cash conversion cycle can increase liquidity needs if demand or collections deteriorate., Investment securities of ¥14.46bn and valuation differences on securities of ¥7.68bn create equity sensitivity to market-value movements., Interest-bearing debt totals ¥32.69bn; current leverage and interest coverage are sound, but debt servicing remains sensitive to a sustained downturn in chemical profitability..

Key concerns include Highest priority: convert the sharp profit recovery into cash by reducing the 234-day cash conversion cycle and preventing further inventory accumulation ahead of demand., High priority: assess whether Precision Chemicals can sustain profitability above the full-year implied margin, as Q1's 22.7% segment margin was exceptionally stronger than the prior-year 4.8%., Moderate priority: monitor FX gains because Q1 ordinary income exceeded operating income partly through non-operating currency effects., Moderate priority: monitor the expanded short-term borrowing balance alongside the current portion of long-term debt..

Investment Implications

Key takeaways include Revenue increased 30.6%, while operating income increased 410.7%, reflecting a major recovery in gross margin and favorable operating leverage., The operating margin reached 20.1%, up 1,500bp year on year, while net margin reached 16.4%., Precision Chemicals is the core earnings engine, with ¥16.52bn of revenue and ¥3.75bn of segment profit., Balance-sheet liquidity and leverage metrics are sound, with a 209.6% current ratio, 2.57x cash-to-short-term-debt, 0.81x debt-to-equity, and 29.47x interest coverage., Working-capital efficiency is the main constraint on earnings quality, given the 91-day receivables period, 196-day production-inventory period, and 234-day cash conversion cycle., The FY2027 forecast dividend of ¥36 per share implies a conservative 27.2% payout ratio based on forecast EPS..

Metrics to watch include Precision Chemicals revenue growth, segment margin, and profit contribution., Consolidated gross margin and operating margin relative to Q1's 34.4% and 20.1%., Annualized receivable days, inventory days, and cash conversion cycle., Inventory balance relative to revenue growth and demand conditions., Short-term loan balance, cash-to-short-term-debt coverage, and current portions of long-term borrowings., FX gains or losses as a proportion of operating income., Quarterly progress against the ¥95.0bn revenue, ¥11.3bn operating-income, and ¥7.6bn net-income forecasts..

Regarding relative positioning, The company currently displays profitability and annualized ROE metrics above broad manufacturing benchmarks, supported by a strong Precision Chemicals recovery and conservative leverage. Its relative financial profile is strengthened by high liquidity and robust interest coverage, but its operating profile is less favorable on working-capital efficiency, where receivable, inventory, and cash-conversion metrics are materially above standard manufacturing thresholds.